Tourmaline Bio
New York
About Tourmaline Bio
Tourmaline Bio develops medicines for inflammatory and immune diseases. The company focuses on creating a pipeline of drug candidates for patients with life-altering conditions. It aims to develop new treatments for areas with high unmet medical needs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Total funding: $359.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jan 2024)
- Ticker: nasdaq:TRML
- Website: tourmalinebio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Clinical Trials, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/tourmaline-bio-83869 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.